Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Employees - 55000,
CEO - Mr. James E. Davis,
Sector - Healthcare,
Country - US,
Market Cap - 19.57B
Altman ZScore(max is 10): 3.12, Piotroski Score(max is 10): 6, Working Capital: $634000000, Total Assets: $15797000000, Retained Earnings: $9490000000, EBIT: 1296000000, Total Liabilities: $8868000000, Revenue: $10158000000
AryaFin Target Price - $205.23 - Current Price $175.28 - Analyst Target Price $184.69
Ticker | DGX |
Index | S&P 500 |
Curent Price | 175.28 |
Change | -0.34% |
Market Cap | 19.57B |
Average Volume | 1.37M |
Income | 892.00M |
Sales | 10.16B |
Book Value/Share | 61.87 |
Cash/Share | 1.68 |
Dividend Est | 3.03 (1.73%) |
Dividend TTM | 3.05 (1.74%) |
Dividend Ex-Date | Apr 07, 2025 |
Employees | 56000 |
Moving Avg 20days | 4.72% |
Moving Avg 50days | 3.48% |
Moving Avg 200days | 11.12% |
Shares Outstanding | 112.00M |
Earnings Date | Apr 22 BMO |
Inst. Ownership | 91.18% |
Price/Earnings | 22.15 |
Forwad P/E | 16.63 |
PE Growth | 2.64 |
Price/Sales | 1.93 |
Price/Book | 2.83 |
Price/Cash | 104.08 |
Price/FCF | 18.53 |
Quick Ratio | 1.31 |
Current Ratio | 1.44 |
Debt/Equity | 0.95 |
Return on Assets | 6.00% |
Return on Equity | 13.35% |
Return on Investment | 6.69% |
Gross Margin | 31.71% |
Ops Margin | 14.38% |
Profit Margin | 8.78% |
RSI | 61.59 |
BETA(β) | 0.52 |
From 52week Low | 30.76% |
From 52week High | -2.01% |
EPS | 7.91 |
EPS next Year | 10.54 |
EPS next Qtr | 2.57 |
EPS this Year | 8.64% |
EPS next 5 Year | 8.38% |
EPS past 5 Year | 4.04% |
Sales past 5 Year | 5.68% |
EPS Y/Y | 6.43% |
Sales Y/Y | 9.38% |
EPS Q/Q | 12.47% |
Sales Q/Q | 12.09% |
Sales Surprise | 0.83% |
EPS Surprise | 2.71% |
ATR(14) | 5.07 |
Perf Week | 7.01% |
Perf Month | 5.20% |
Perf Quarter | 12.88% |
Perf Year | 28.22% |
Perf YTD | 16.19% |
Target Price | 184.69 |
AryaFin Engine© - An AI FinTech Venture - 2024-25 Disclaimer